283 related articles for article (PubMed ID: 12240780)
21. Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients.
Shorr AF; Khashab MM; Xiang JX; Tennenberg AM; Kahn JB
Respir Med; 2006 Dec; 100(12):2129-36. PubMed ID: 16730170
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness of levofloxacin for adult community-acquired pneumonia caused by macrolide-resistant Streptococcus pneumoniae: integrated results from four open-label, multicenter, phase III clinical trials.
Fogarty CM; Greenberg RN; Dunbar L; Player R; Marrie TJ; Kojak CM; Morgan N; Williams RR
Clin Ther; 2001 Mar; 23(3):425-39. PubMed ID: 11318077
[TBL] [Abstract][Full Text] [Related]
23. An open-label, randomized comparison of levofloxacin and amoxicillin/clavulanate plus clarithromycin for the treatment of hospitalized patients with community-acquired pneumonia.
Lin TY; Lin SM; Chen HC; Wang CJ; Wang YM; Chang ML; Wang CH; Liu CY; Lin HC; Yu CT; Hsieh LL; Kuo HP; Huang CD
Chang Gung Med J; 2007; 30(4):321-32. PubMed ID: 17939262
[TBL] [Abstract][Full Text] [Related]
24. Antibiotic treatment patterns, costs, and resource utilization among patients with community acquired pneumonia: a US cohort study.
Llop CJ; Tuttle E; Tillotson GS; LaPlante K; File TM
Hosp Pract (1995); 2017 Feb; 45(1):1-8. PubMed ID: 28064542
[TBL] [Abstract][Full Text] [Related]
25. Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study.
West M; Boulanger BR; Fogarty C; Tennenberg A; Wiesinger B; Oross M; Wu SC; Fowler C; Morgan N; Kahn JB
Clin Ther; 2003 Feb; 25(2):485-506. PubMed ID: 12749509
[TBL] [Abstract][Full Text] [Related]
26. Levofloxacin versus ceftriaxone plus clarithromycin in the treatment of adults with community-acquired pneumonia requiring hospitalization.
Querol-Ribelles JM; Tenías JM; Querol-Borrás JM; Labrador T; Nieto A; González-Granda D; Martínez I
Int J Antimicrob Agents; 2005 Jan; 25(1):75-83. PubMed ID: 15620830
[TBL] [Abstract][Full Text] [Related]
27. FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.
File TM; Low DE; Eckburg PB; Talbot GH; Friedland HD; Lee J; Llorens L; Critchley IA; Thye DA;
J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii19-32. PubMed ID: 21482566
[TBL] [Abstract][Full Text] [Related]
28. FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.
Low DE; File TM; Eckburg PB; Talbot GH; David Friedland H; Lee J; Llorens L; Critchley IA; Thye DA;
J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii33-44. PubMed ID: 21482568
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of azithromycin in the treatment of community-acquired pneumonia, including patients with macrolide-resistant Streptococcus pneumoniae infection.
Yanagihara K; Izumikawa K; Higa F; Tateyama M; Tokimatsu I; Hiramatsu K; Fujita J; Kadota J; Kohno S
Intern Med; 2009; 48(7):527-35. PubMed ID: 19336954
[TBL] [Abstract][Full Text] [Related]
30. Comparative efficacy and safety analysis of CSE-1034: An open labeled phase III study in community acquired pneumonia.
Chaudhary M; Ayub SG; Mir MA;
J Infect Public Health; 2018; 11(5):691-697. PubMed ID: 29803638
[TBL] [Abstract][Full Text] [Related]
31. Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults.
Drehobl MA; De Salvo MC; Lewis DE; Breen JD
Chest; 2005 Oct; 128(4):2230-7. PubMed ID: 16236879
[TBL] [Abstract][Full Text] [Related]
32. Azithromycin plus β-lactam versus levofloxacin plus β-lactam for severe community-acquired pneumonia: A retrospective nationwide database analysis.
Suzuki J; Sasabuchi Y; Hatakeyama S; Matsui H; Sasahara T; Morisawa Y; Yamada T; Yasunaga H
J Infect Chemother; 2019 Dec; 25(12):1012-1018. PubMed ID: 31227381
[TBL] [Abstract][Full Text] [Related]
33. Experiences at a large teaching hospital with levofloxacin for the treatment of community-acquired pneumonia.
Clark LC; Davis CW
Am J Health Syst Pharm; 2000 Nov; 57 Suppl 3():S10-3. PubMed ID: 11098314
[TBL] [Abstract][Full Text] [Related]
34. Clinical efficacy and safety of moxifloxacin versus levofloxacin plus metronidazole for community-acquired pneumonia with aspiration factors.
Sun T; Sun L; Wang R; Ren X; Sui DJ; Pu C; Ren Y; Liu Y; Yang Z; Li F
Chin Med J (Engl); 2014; 127(7):1201-5. PubMed ID: 24709166
[TBL] [Abstract][Full Text] [Related]
35. Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. The Azithromycin Intravenous Clinical Trials Group.
Plouffe J; Schwartz DB; Kolokathis A; Sherman BW; Arnow PM; Gezon JA; Suh B; Anzuetto A; Greenberg RN; Niederman M; Paladino JA; Ramirez JA; Inverso J; Knirsch CA
Antimicrob Agents Chemother; 2000 Jul; 44(7):1796-802. PubMed ID: 10858333
[TBL] [Abstract][Full Text] [Related]
36. Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors.
Leroy O; Saux P; Bédos JP; Caulin E
Chest; 2005 Jul; 128(1):172-83. PubMed ID: 16002932
[TBL] [Abstract][Full Text] [Related]
37. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
[TBL] [Abstract][Full Text] [Related]
38. Linezolid versus ceftriaxone/cefpodoxime in patients hospitalized for the treatment of Streptococcus pneumoniae pneumonia.
San Pedro GS; Cammarata SK; Oliphant TH; Todisco T;
Scand J Infect Dis; 2002; 34(10):720-8. PubMed ID: 12477321
[TBL] [Abstract][Full Text] [Related]
39. A prospective, randomized, multicenter comparative study of clinafloxacin versus a ceftriaxone-based regimen in the treatment of hospitalized patients with community-acquired pneumonia.
Petermann W; Alegre-Martin J; Odenholt I; Phillips MJ; Willcox PA; Tack K; Trostmann U; Welling L
Scand J Infect Dis; 2001; 33(11):832-7. PubMed ID: 11760164
[TBL] [Abstract][Full Text] [Related]
40. Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia.
Oldach D; Clark K; Schranz J; Das A; Craft JC; Scott D; Jamieson BD; Fernandes P
Antimicrob Agents Chemother; 2013 Jun; 57(6):2526-34. PubMed ID: 23507282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
